High-Level Resistance of Toxigenic Clostridioides difficile Genotype to Macrolide-Lincosamide- Streptogramin B in Community Acquired Patients in Eastern China
Authors Zhao L, Luo Y, Bian Q, Wang L, Ye J, Song X, Jiang J, Tang YW, Wang X, Jin D
Received 16 November 2019
Accepted for publication 26 December 2019
Published 17 January 2020 Volume 2020:13 Pages 171—181
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Longyou Zhao, 1,* Yun Luo, 2,* Qiao Bian, 3, 4 Liqian Wang, 5 Julian Ye, 6 Xiaojun Song, 4, 7 Jianmin Jiang, 6, 8 Yi-Wei Tang, 9–11 Xianjun Wang, 5 Dazhi Jin 4, 7
1Lishui Second People’s Hospital, Lishui, Zhejiang, People’s Republic of China; 2School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia; 3School of Medicine, Ningbo University, Ningbo, Zhejiang, People’s Republic of China; 4Centre of Laboratory Medicine, Zhejiang Provincial People Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 5Department of Laboratory Medicine, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China; 6Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, People’s Republic of China; 7School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 8Key Laboratory of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China; 9Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 10Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA; 11Cepheid, Danaher Diagnostic Platform, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Dazhi Jin
Centre of Laboratory Medicine, Zhejiang Provincial People Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, Zhejiang 310014, People’s Republic of China
Xianjun Wang Tel/Fax +86-571-56007158
Background: Clostridioides difficile resistant to macrolide-lincosamide-streptogramin B (MLSB) has not been reported in China.
Methods: In a cross-sectional study in two tertiary hospitals, C. difficile isolates from stool specimens from community-onset, hospital-associated diarrheal patients were analyzed for toxin genes, genotype, and antibiotic resistance, and the patients’ clinical charts were reviewed.
Results: A total of 190 (15.2%) isolates (102 A+B+ and 88 A−B+) from 1250 community acquired (CA) patients were recovered and all were susceptible to vancomycin and metronidazole. High-level resistance (minimum inhibitory concentration > 128 mg/L) to erythromycin and clindamycin was recorded in 77.9% and 88.4% of the tested isolates, respectively. Furthermore, 89.3% (159/178) of the isolates resistant to MLSB carried the erythromycin resistance methylase gene (ermB). The statistically significant factors associated with C. difficile infection (CDI) induced by A−B+ isolates with MLSB resistance included a severity score of > 2 (odds ratio [95% confidence interval], 7.43 [2.31– 23.87]) and platelet count (cells × 10 9 cells/L) < 100 [5.19 (1.58– 17.04)]. The proportion of A−B+ increased with enhanced CDI severity (x 2 = 21.62, P < 0.001), which was significantly higher than that of ermB-positive A+B+ in severity score of 4 (x 2 = 8.61, P = 0.003). The average severity score of ermB-positive isolates was significantly higher than that of ermB-negative isolates in A−B+ (Z = − 2.41, P = 0.016).
Conclusion: The ermB-positive A−B+ C. difficile with MLSB resistance is described for the first time as a potential epidemic clone inducing severe CDI in CA diarrheal patients in Eastern China.
Keywords: Clostridioides difficile, molecular characteristic, macrolide-lincosamide-streptogramin B resistance
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]